New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The medical device giant Medtronic plc (NYSE: MDT ) announced its second quarter fiscal results ahead of market open today — so far, the market's reaction has been lukewarm ...

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&P 500 also rose, gaining, 0.49% to 5,922.41.Check This Out: This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayLeading and Lagging SectorsInformation technology shares rose by 0.6% on Tuesday.In trading on Tuesday, materials shares fell by 0.6%.Top Headli ...

Medtronic plc (NYSE:MDT) Q2 2025 Earnings Conference Call November 19, 2024 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Gary Corona - Interim CFO Brad Welnick - VP, IR Que Dallara - EVP and President, Diabetes Operating Unit Sean Salmon - EVP and President, Cardiovascular Portfolio Mike Marinaro - EVP and President, Medical Surgical Portfolio and Surgical Operating Unit Brett Wall - EVP and President, Neuroscience Conference Call Participants Larry Bie ...

Medtronic plc (MDT) reported adjusted earnings per share (EPS) of $1.26 for the second-quarter fiscal 2025, up 0.8% from the year-ago quarter’s figure. The figure also beat the Zacks Consensus Estimate by 1.61%. Currency-adjusted EPS for the reported quarter was $1.35.Without certain one-time adjustments — including amortization, restructuring and associated costs, certain litigation charges and acquisition-related costs, among others — GAAP EPS was 99 cents, a 45.6% improvement from the year-ago quarter’s ...

For the quarter ended October 2024, Medtronic (MDT) reported revenue of $8.4 billion, up 5.3% over the same period last year. EPS came in at $1.26, compared to $1.25 in the year-ago quarter.The reported revenue represents a surprise of +1.75% over the Zacks Consensus Estimate of $8.26 billion. With the consensus EPS estimate being $1.24, the EPS surprise was +1.61%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectat ...

Core Points - Medtronic reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.24 per share, and showing a slight increase from $1.25 per share a year ago, resulting in an earnings surprise of 1.61% [1] - The company achieved revenues of $8.4 billion for the quarter ended October 2024, surpassing the Zacks Consensus Estimate by 1.75% and increasing from $7.98 billion year-over-year [2] - Medtronic has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Future Outlook - The immediate price movement of Medtronic's stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - Current consensus EPS estimate for the upcoming quarter is $1.37 on revenues of $8.41 billion, while for the current fiscal year, it is $5.44 on revenues of $33.6 billion [8] - The estimate revisions trend for Medtronic is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [7] Industry Context - The Medical - Products industry, to which Medtronic belongs, is currently in the top 50% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]

Exhibit 99.1 Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 NEWS RELEASE Contacts: FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland – Nov. 19, 2024 – Medtronic plc (NYSE: MDT) today announced finan ...

Delivering on commitments, executing ahead of expectations, and raising guidanceInnovation driving sustained growth across many franchises:  TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and NeuromodulationGALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024.Key Highlights Revenue of $8.4 billion increased 5.3% as reported and 5.0% organic GAAP diluted earnings per ...

Analysts on Wall Street project that Medtronic (MDT) will announce quarterly earnings of $1.24 per share in its forthcoming report, representing a decline of 0.8% year over year. Revenues are projected to reach $8.26 billion, increasing 3.5% from the same quarter last year. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. A ...